Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: One-year results of phase III, double-blind, randomized trial

American Journal of Transplantation

Volumn 14, Issue 12, 2014, Pages 2796-2806

  Budde, K ^a   Bunnapradist, S ^b   Grinyo, J M ^c   Ciechanowski, K ^d   Denny, J E ^e   Silva, H T ^f   Rostaing, L ^g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d POMERANIAN MEDICAL UNIVERSITY   (Poland)

^e HENRY FORD HOSPITAL   (United States)

^f HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^g CHU RANGUEIL   (France)

Author keywords

calcineurin inhibitor: tacrolimus; clinical research practice; clinical trial; immunosuppressant; immunosuppression immune modulation; kidney transplantation nephrology

Indexed keywords

CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; TACROLIMUS; TRIACYLGLYCEROL; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ACUTE HEART INFARCTION; ADULT; ANEMIA; ARTICLE; CARDIOPULMONARY ARREST; CARDIOPULMONARY INSUFFICIENCY; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DE NOVO KIDNEY TRANSPLANT; DE NOVO KIDNEY TRANSPLANTATION; DELAYED GRAFT FUNCTION; DEMOGRAPHY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SEPSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; ADVERSE EFFECTS; CLINICAL TRIAL; DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR; TIME;

ADULT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; TACROLIMUS; TIME FACTORS;

EID: 84910647641     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12955     Document Type: Article

References (28)

1. Webster AC, Taylor RRS, Chapman JR, Craig JC., Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; Art. No.: CD003961. DOI: 10.1002/14651858.CD003961.pub2
2. Organ Procurement and Transplantation Network. (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2012 Annual Data Report. Rockville, MD: Department of Health and Human Services; Health Resources and Services Administration; 2014.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1-S157.
4. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM181006.pdf. Accessed February 2, 2014.
5. Prograf Prescribing Information. Northbrook, IL: Astellas Pharma US, Inc; 2013.
6. Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T., High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010; 25: 2757-2763.
7. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR., The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-1884.
8. Claxton AJ, Cramer J, Pierce C., A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
9. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC., Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15: e22-e33.
10. Morrissey PE, Reinert S, Yango A, Gautam A, Monaco A, Gohh R., Factors contributing to acute rejection in renal transplantation: The role of noncompliance. Transplant Proc 2005; 37: 2044-2047.
11. Michelon T, Dominguez V, Losekan A, et al. Kidney graft failure due to noncompliance. Transplant Proc 1999; 31: 3031-3032.
12. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf. Accessed February 2, 2014.
13. MeltDose® Technology by the US Patent and Trademark Office, US Patent No. 7,217, 431.
14. Nigro V, Glicklich A, Weinberg J., Improved bioavailability of MELTDOSE once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24-hrs: A scintigraphic and pharmacokinetic evaluation. Am J Transplant 2013; 13 (Suppl 5): 339.
15. Nigro V, Glicklich A, Weinberg J., Flexible dosing of once-daily LCP-Tacro tablets: Morning vs. evening randomized crossover chronopharmacokinetic study. Paper presented at the AST/ESOT Joint Meeting, Oct. 12-14, 2012, Nice, France.
16. Alloway R, Mulgaonkar S, Ueda K, Cohen DBK., A phase 2 randomized study of the pharmacokinetics, safety and efficacy of LCP-Tacro tablets once-a-day vs Prograf capsules twice-a-day in de novo kidney transplants. Am J Transplant 2011; 11 (Suppl 2): 355.
17. Alloway RR, Mulgaonkar S, Bowers VD., A phase 2b, open-label, multi-center, prospective, randomized study to compare the pharmacokinetics and safety of LCP-Tacro™ tablets once-a-day to Prograf® capsules twice-a-day in de novo kidney transplant patients. Am J Transplant 2009; 9 (Suppl 2): 414.
18. DuBay DA, Alloway RR, Alsina AE, et al. A phase 2b, open-label, multicenter, prospective, randomized study to compare the pharmacokinetics and safety of LCP-Tacro™ tablets once-a-day to Prograf® capsules twice-a-day in de novo liver transplant patients. Liver Transpl 2009; 15 (Suppl 7): S134-S135.
19. Alloway RR, Eckhoff DE, Washburn WK, Teperman LW., Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): Phase II trial of stable liver transplant recipients. Liver Transpl 2014; 20: 564-575.
20. Bunnapradist S, Ciechanowski K, West-Thielke P, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): The phase III randomized MELT trial. Am J Transplant 2013; 13: 760-769.
21. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: A randomized, open-label trial. Am J Transplant 2009; 9: 2505-2513.
22. Krämer BK, Charpentier B, Bäckman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: A randomized phase III study. Am J Transplant 2010; 10: 2632-2643.
23. Silva HT, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595-608.
24. Feldman HI, Hackett M, Bilker W, Strom BL., Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunosuppressive agents. Pharmacoepidemiol Drug Saf 1999; 8: 1-14.
25. Germani G, Lazzaro S, Gnoato F, et al. Nonadherent behaviors after solid organ transplantation. Transplant Proc 2011; 43: 318-323.
26. Chisholm MA., Issues of adherence to immunosuppressant therapy after solid-organ transplantation. Drugs 2002; 62: 567-575.
27. Laederach-Hofmann K, Bunzel B., Noncompliance in organ transplant recipients: A literature review. Gen Hosp Psychiatry 2000; 22: 412-424.
28. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.